Abstract:704 Background: KRAS G12C mutation occurs in approximately 1% of pancreatic ductal adenocarcinoma (PDA). KRAS G12C inhibitors have a reported response rate of 21-33% in patients with previously treated advanced PDA. KRAS is a known modulator of the tumor immune microenvironment (TME) and a greater understanding of the TME in KRAS G12C as compared to other mutations is crucial for developing rational therapeutic combination strategies in PDA. Methods: We performed multiplex fluorescent immunohistochemistry (mfIHC) on tissue obtained from patients with histologically confirmed PDA (KRAS G12C n=8; other mutations n=108) and normal pancreas (n=38). Serial staining was performed using antibodies against CD3, CD8, CD163, FoxP3 and PanCK for simple and complex phenotyping as well as spatial analyses in the TME. After tyramide based signal amplification, the slides were imaged at 20x magnification using the Mantra Quantitative Pathology workstation. Images were analyzed using inForm Cell Analysis software (Akoya Biosciences). All statistical analyses were performed using JMP Pro 13.2.0. Differences in phenotype, distances, and engagement were evaluated by 2-tailed Student’s t test or ANOVA. Results: Patients with KRAS G12C mutation had a median age of 70 (45-73) years of which majority (n=5, 62.5%) were men with advanced stage at diagnosis (n=6; 75%). The median overall survival is not yet reached (n=5, alive) after a median follow-up time of 14.4 months through reverse censoring methodology. When examining cellular infiltration, CD8+ cytotoxic T lymphocyte cells were significantly more abundant in the G12C TME compared to the cancer and non-cancer controls (p <0.01). Additionally, the relative frequency of CD4+ and Tregs (CD3+/CD8-/FoxP3+) were also significantly higher in G12C (p<0.01). The percentage of CD163+ antigen presenting cells (APCs) out of all cells was significantly higher in G12C (p<0.01) while the percentage of non-functional APCs (PDL1+/CD163+) of all APCs was significantly higher in G12C than cancer and non-cancer controls (p=0.03). In comparison, the PDL1+ epithelial cells were much lower in G12C TME (p<0.01). The cellular engagement and interaction data from the spatial analysis in the TME will be presented at the meeting. Conclusions: We identified increased infiltration of cytotoxic T lymphocytes and APCs in PDA patients with KRAS G12C mutations relative to other mutations and non-cancerous pancreata. Furthermore, while all PDAs had elevated PD-L1 expression on APCs, KRAS G12C tumors had minimal expression on epithelial cells suggesting a mutation specific impact and a potential role of immune checkpoint inhibitors in combination with G12C inhibitors.

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer

PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology.

PAK Inhibition by PF-3758309 Enhanced the Sensitivity of Multiple Chemotherapeutic Reagents in Patient-Derived Pancreatic Cancer Cell Lines.

Kras as a key oncogene and therapeutic target in pancreatic cancer

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications

Critical Role of Oncogenic KRAS in Pancreatic Cancer (Review)

Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues

PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

The Role of Phosphatidylinositol 3-Kinase Signaling Pathways in Pancreatic Cancer

Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata.

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC

A Special Subtype: Revealing the Potential Intervention and Great Value of KRAS Wildtype Pancreatic Cancer.